Cargando…

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma

The discovery by Morris et al. (1994) of the genes contributing to the t(2;5)(p23;q35) translocation has laid the foundation for a molecular based recognition of anaplastic large cell lymphoma and highlighted the need for a further stratification of T-cell neoplasia. Likewise the detection of anapla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabbó, Fabrizio, Barreca, Antonella, Piva, Roberto, Inghirami, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2012
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355932/ https://www.ncbi.nlm.nih.gov/pubmed/22649787 http://dx.doi.org/10.3389/fonc.2012.00041

Ejemplares similares

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma
por: Mura, Giulia, et al.
Publicado: (2023)

Pathobiology of Anaplastic Large Cell Lymphoma
por: Piccaluga, Pier Paolo, et al.
Publicado: (2010)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Pathobiology of ALK-negative anaplastic large cell lymphoma
por: Pileri, Stefano A., et al.
Publicado: (2011)

ALK-positive anaplastic large cell lymphoma in adults
por: Gromowsky, Matthew J, et al.
Publicado: (2023)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

The heterogeneous landscape of ALK negative ALCL
por: Mereu, Elisabetta, et al.
Publicado: (2017)

Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma
por: Satou, Akira, et al.
Publicado: (2020)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
por: Stadler, Serena, et al.
Publicado: (2018)

Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant–Associated Anaplastic Large-Cell Lymphoma
por: Turner, Suzanne D., et al.
Publicado: (2020)

IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas
por: Bandini, Cecilia, et al.
Publicado: (2018)

Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma
por: Hu, G, et al.
Publicado: (2017)

From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
por: Werner, Michael T., et al.
Publicado: (2017)

Updates in pathobiological aspects of anaplastic large cell lymphoma
por: Wu, Rui, et al.
Publicado: (2023)

ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment
por: Chioureas, Dimitrios, et al.
Publicado: (2022)

ALK-positive anaplastic large cell lymphoma that presented as pleural effusion
por: Kim, Do Hwan, et al.
Publicado: (2022)

ALK-Positive Anaplastic Large Cell Lymphoma Associated With Hemophagocytic Lymphohistiocytosis
por: Chao, Shing, et al.
Publicado: (2023)

Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of TRAF1-ALK-Associated Anaplastic Large Cell Lymphoma
por: Agarwal, Indu, et al.
Publicado: (2020)

Case Report: Clinical response to anaplastic lymphoma kinase inhibitor-based targeted therapy in uterine inflammatory myofibroblastic tumor harboring ALK-IGFBP5 fusion
por: Zhao, Ting, et al.
Publicado: (2023)

Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
por: Shigeta, Naoko, et al.
Publicado: (2023)

Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy
por: Buetti-Dinh, Antoine, et al.
Publicado: (2016)

Endobronchial ALK-Positive Anaplastic Large Cell Lymphoma Presenting Massive Hemoptysis
por: Kim, Hee Kyung, et al.
Publicado: (2015)

Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma
por: Fuchs, Steffen, et al.
Publicado: (2019)

Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma
por: Arosio, Giulia, et al.
Publicado: (2021)

Granulomatous Inflammation in a Patient with ALK-Negative Anaplastic Large Cell Lymphoma
por: Kandemir Alibakan, Özlem, et al.
Publicado: (2022)

A Case of ALK-Positive Anaplastic Large Cell Lymphoma of the Male Breast
por: Wang, Xu, et al.
Publicado: (2023)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
por: Singh, Vijay Kumar, et al.
Publicado: (2019)

Anaplastic large cell lymphoma ALK-positive variant of primary bone lymphoma associated with melanoma
por: Tutaeva, Victoria V, et al.
Publicado: (2023)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Current Progress in Breast Implant-Associated Anaplastic Large Cell Lymphoma
por: Wang, Yichen, et al.
Publicado: (2022)

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
por: Haque, Moinul, et al.
Publicado: (2019)

TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature
por: Xiao, Andrew, et al.
Publicado: (2023)

Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
por: Mitou, Géraldine, et al.
Publicado: (2015)

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes
por: Boi, Michela, et al.
Publicado: (2016)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma
por: Knörr, Fabian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oj043iaeotru254uuq0a130dnr